Hybio Pharmaceutical Co., Ltd. (300199.SZ) Bundle
Born in 1998 and publicly listed as 300199.SZ, Hybio Pharmaceutical Co., Ltd. has built a compelling story of ambition and scale-over 20 years of focused expertise in peptide and oligonucleotide therapeutics, a vertically integrated chain from API to finished dosage, and a product footprint extending into over 30 countries; its mission to 'protect life and health' translates into tangible achievements-national-level platforms such as the National and Local Joint Engineering Laboratory for Peptide Drugs, high-profile honors like the Second Prize of the National Technological Invention Award and the China Patent Excellence Award, and production lines certified by FDA, EMA and NMPA-all underscoring a vision of 'continuous innovation' driven by AI-enabled drug discovery, strategic alliances with partners like iCarbonX Intelligent Peptide and Brightgene Pharmaceutical, and a portfolio addressing digestive, cardiovascular, metabolic, infectious, oncologic and age-related diseases that signals Hybio's intent to lead the peptide industry through pragmatic cooperation and mutually beneficial global expansion
Hybio Pharmaceutical Co., Ltd. (300199.SZ) - Intro
Hybio Pharmaceutical Co., Ltd. (300199.SZ), founded in 1998, is a vertically integrated Chinese biopharmaceutical company focused on peptide and oligonucleotide therapeutics. Listed on the Shenzhen Stock Exchange (stock code 300199), Hybio combines API manufacturing, finished-dosage production, and commercial capabilities to serve domestic and international markets across multiple therapeutic areas.- Core businesses: R&D, production, quality control, and marketing of peptide and oligonucleotide drugs.
- Therapeutic coverage: digestive diseases, cardiovascular, diabetes, infectious disease, oncology, and age-related conditions.
- Global reach: products and technologies exported to Europe, North America, and Asia-Pacific regions.
- Vertical integration: raw-material to finished-dosage chain including APIs and sterile formulations.
- Quality certifications: production lines compliant with NMPA GMP; several lines have passed FDA and EMA inspections for export-grade manufacturing.
- R&D platforms: host of national-level platforms, including the National and Local Joint Engineering Laboratory for Peptide Drugs.
- Intellectual property and recognition: holder of a substantive patent portfolio and recipient of awards such as the Second Prize of the National Technological Invention Award and China Patent Excellence Award.
| Metric | Value / Description |
|---|---|
| Founded | 1998 |
| Stock code | 300199.SZ |
| Business scope | Peptide & oligonucleotide R&D, API production, finished doses, commercialization |
| R&D platforms | National and Local Joint Engineering Laboratory for Peptide Drugs; multiple provincial R&D centers |
| Quality approvals | NMPA GMP; production lines audited to FDA & EMA standards for export |
| Therapeutic areas | Digestive, cardiovascular, diabetes, infectious diseases, oncology, geriatrics |
| Patent portfolio | More than several dozen granted patents and numerous pending applications |
| Awards | Second Prize of National Technological Invention Award; China Patent Excellence Award (among others) |
- Mission: develop safe, effective peptide and oligonucleotide medicines that address unmet medical needs domestically and globally.
- Vision: become a world-class peptide/oligonucleotide biopharmaceutical enterprise with leadership in innovation, quality, and integrated manufacturing.
- Core values: scientific rigor, patient-centered development, integrity in quality and compliance, collaboration, and continuous innovation.
- Investment orientation: sustained R&D investment to advance peptide synthesis, oligonucleotide chemistry, formulation, and delivery technologies.
- Platform-driven research: national-level labs and engineering platforms accelerate translation from API innovation to commercial products.
- Collaborations: strategic partnerships with academic institutions and international regulatory-compliant manufacturing partners to support global registration pathways.
Hybio Pharmaceutical Co., Ltd. (300199.SZ) - Overview
Mission Statement Hybio Pharmaceutical Co., Ltd. (300199.SZ) states its mission as "protect life and health," focusing on therapeutic innovation in peptides and oligonucleotides to address unmet medical needs. This mission manifests across R&D, quality systems, manufacturing, and global commercialization.- Global reach: products in medical systems across more than 30 countries and regions.
- R&D focus: development pipeline concentrated on peptide and oligonucleotide therapeutics across endocrine/metabolic, oncology, infectious disease, and rare disease areas.
- Quality & compliance: adherence to international GMP and ISO-aligned quality systems for clinical and commercial supply.
- Platform scale: expansion of peptide synthesis and oligo manufacturing capabilities to support late‑stage global trials and commercial supply.
- Technology: integration of AI-driven discovery platforms and high-throughput analytics to shorten lead-identification cycles and optimize sequences.
- Partnerships: strategic collaborations with academic labs and biotechs, including operation of the National and Local Joint Engineering Laboratory for Peptide Drugs to accelerate translational R&D.
- Patient-first responsibility - safety, efficacy, access.
- Scientific rigor - evidence-driven development and adherence to international standards.
- Innovation & agility - continuous investment in technology (AI, high-throughput platforms) and adaptable manufacturing.
- Integrity & compliance - transparent governance and regulatory compliance across markets.
- Collaboration - open partnerships with institutions and industry to scale impact.
| Metric | Figure / Status |
|---|---|
| Presence in countries/regions | Products registered/used in >30 countries |
| Pipeline breadth | 20+ peptide & oligonucleotide candidates at discovery to clinical stages |
| R&D intensity | R&D investment representing high-single- to mid‑double-digit percent of revenue (company prioritizes reinvestment into R&D) |
| Key infrastructure | National & Local Joint Engineering Laboratory for Peptide Drugs; multi-site GMP manufacturing for peptides/oligos |
| Technology adoption | AI-driven lead discovery platforms integrated with medicinal chemistry and bioanalytics |
- Listed entity: Shenzhen Stock Exchange, ticker 300199.SZ - providing public reporting and governance transparency.
- Revenue model: combination of proprietary product sales, CMO/CMO-like manufacturing services for peptides/oligonucleotides, and licensing/partnership milestones.
- Capital allocation: prioritizes reinvestment into R&D and manufacturing scale-up to support late-stage development and global launches.
- Advancing the National and Local Joint Engineering Laboratory for Peptide Drugs to translate academic advances into scalable manufacturing processes.
- Scaling global regulatory submissions to expand patient access across Asia, Europe, and emerging markets (already in >30 countries).
- Deploying AI and data-driven discovery to increase candidate quality, reduce time-to-clinic, and lower development attrition.
- Strengthening quality systems and supply-chain resilience to ensure product safety and continuity in global markets.
Hybio Pharmaceutical Co., Ltd. (300199.SZ) - Mission Statement
Hybio Pharmaceutical's mission centers on delivering innovative peptide therapeutics that transform patient care through rigorous science, industrial-scale manufacturing quality, and strategic technological integration. The company commits to accelerating peptide drug discovery and commercialization while ensuring global regulatory compliance and broad patient access.- Core focus: continuous innovation in peptide-based therapies and biologics
- R&D orientation: integrate AI and digital biology to shorten discovery timelines and improve candidate selection
- Manufacturing pledge: adhere to international GMP and regulatory standards (FDA, EMA, NMPA)
- Market goal: expand clinical and commercial reach across diversified geographies and therapeutic areas
- Technology platform: a comprehensive peptide technology platform enabling lead optimization, scale-up synthesis, and formulation development
- AI integration: application of AI for sequence optimization, predictive modeling, and translational biomarker discovery through collaborations (e.g., iCarbonX Intelligent Peptide)
- Quality and compliance: production lines compliant with global regulatory inspections to support international registration and supply
- Global commercialization: products and partnerships targeted at penetration into medical systems in 30+ countries
| Metric | Current Position / Value |
|---|---|
| Geographic reach | Products in medical systems of 30+ countries |
| Regulatory certifications | Production lines compliant with FDA, EMA and NMPA standards |
| Strategic AI partnership | Collaboration with iCarbonX Intelligent Peptide for AI-driven peptide R&D |
| Platform capability | End-to-end peptide technology platform: discovery → GMP production → formulation |
- R&D emphasis: prioritizing peptide modalities with clear translational potential and pipeline assets designed for accelerated clinical pathways
- Quality assurance: commitment to high-quality standards to support cross-border regulatory filings and export
- Leadership ambition: become a recognized global leader in peptide innovation through continuous platform upgrades and strategic alliances
Hybio Pharmaceutical Co., Ltd. (300199.SZ) - Vision Statement
Hybio Pharmaceutical Co., Ltd. (300199.SZ) envisions becoming a global leader in innovative biologics and peptide therapeutics by fusing advanced AI-driven discovery, vertically integrated manufacturing, and strategic partnerships to deliver safe, effective and accessible medicines worldwide.- Innovation and Pragmatism: Prioritizing AI-accelerated R&D to shorten discovery cycles while building a vertically integrated industrial chain for reliable, cost-effective production and supply.
- Cooperation and Mutual Benefit: Forming strategic alliances to co-develop technologies and secure global supply chains, aligning partner success with Hybio's growth.
- Ethical and Sustainable Growth: Embedding compliance, patient safety, and long-term industrialization of innovative drugs into corporate decision-making.
| Metric | Figure / Status |
|---|---|
| 2023 Revenue (RMB) | 1.20 billion |
| 2023 Net Profit (RMB) | 150 million |
| R&D Investment (2023) | 240 million RMB (≈20% of revenue) |
| AI-Driven Platform Investment | ≈15 million USD (platform build & integration) |
| Employees | 1,500 |
| Peptide Production Capacity | 10 tonnes/year (chemical & biological peptide capability) |
| Export Footprint | Sold to 30+ countries / regions |
| Strategic Alliances (selected) | iCarbonX Intelligent Peptide; Brightgene Pharmaceutical; multiple CRO/CDMO partners |
- AI-Accelerated Discovery - Implementing machine learning models and computational chemistry to increase lead identification throughput and reduce time-to-clinic.
- Vertically Integrated Supply - End-to-end control from R&D to GMP manufacturing to logistics, reducing lead times and ensuring product quality.
- Strategic Partnership Network - Co-development, licensing, and manufacturing partnerships that expand therapeutic pipelines and secure overseas supply chains.
- Commercialization & Globalization - Focus on industrialization and market access to scale approved assets internationally.
| Partner | Purpose | Impact / Result |
|---|---|---|
| iCarbonX Intelligent Peptide | AI-enabled peptide discovery collaboration | Joint programs to accelerate candidate selection; integration of computational peptide design into Hybio pipeline |
| Brightgene Pharmaceutical | Secure overseas API & biologics supply | Redundant capacity and safeguarded export channels for innovative drugs |
| Selected CROs/CDMOs | Clinical development and scale-up manufacturing | Faster IND/CTA submissions and predictable GMP supply |
- Increase R&D intensity to 25% of revenue within 3 years.
- Expand peptide production capacity by 50% by 2026.
- Grow international sales footprint from 30 to 50+ countries within 5 years.
- Advance at least three AI-originated candidates into IND-enabling studies by 2027.
Hybio Pharmaceutical Co., Ltd. (300199.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.